Medizone International to Host Investor Conference Call 

Medizone International to Host Investor Conference Call 

KALAMAZOO, MICH. September 18, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company will host a webcast and conference call today, September 18, 2017, to discuss the recent leadership transition, current priorities and its commercial strategy.

 

Investor Conference Call Details

Date: Monday, September 18, 2017                          Time: 10 AM EST

Materials for the Investor Conference Call will be made available at 7:00 AM EST on September 18, 2017

The slides can be accessed HERE.

Telephone:

North American callers, dial 800 681 1924.  International callers, dial +1 303 223 4393

There is no access code required.  Simply call into the assigned phone number.  

 

An archive of the slides will be available at www.medizoneint.com A replay of the conference call will be available from September 18, 2017 at 12:00 PM EST through September 25, 2017 at 12:00 PM EST by calling 800 633 8284. The access code for the replay is 21859116.  The slides, conference call, and replay are open to all interested parties.

 

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure® system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure® system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

 

For more information, visit:

www.medizoneint.com

Email: [email protected]

Medizone International announces the appointment of David A. Dodd as new Chief Executive Officer

Kalamazoo, MI, September 18, 2017 — Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacterial and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company has appointed David A. Dodd as Chief Executive Officer and as a member of the Company’s Board of Directors.

Effective September 18, 2017, David A. Esposito, current Chairman and interim CEO, will step down from his duties as interim CEO and will remain as Chairman of the Board of Directors.

“As Medizone continues to refine and execute plans to significantly expand our commercial operations, we are thrilled to have David A. Dodd lead our company into this new phase of growth,” commented David A. Esposito. “David brings a tremendous amount of successful experience as a CEO in various life science companies and our board is very confident in his ability to drive growth and value for the company and our shareholders.”

Over the last 12 months, AsepticSure® has been proven to provide significant disinfection in a number of critical need areas such as fitness centers, preparation rooms in funeral homes, building remediation and medicinal nurseries.  These areas provide significant opportunity for growth in the United States and in many markets across the world.  In addition, the Company is seeking FDA clearance for AsepticSure® as a medical device to be used in healthcare environments in the United States.

“On behalf of our employees, the board, and shareholders, I want to thank David Esposito for his leadership during his time as interim CEO.  David’s leadership and strategic planning skills have well positioned the Company for commercial success in the near term,” commented Mr. Dodd.  “I look forward to working with the Board and leading the Company as we build our commercial team to drive sales of AsepticSure® in markets around the world.  I would also like to recognize the effort and commitment of Dr. Michael Shannon, President and Director of Medical Affairs.  Dr. Shannon will continue to play a critical role as we translate the clinical utility of AsepticSure® into commercial success.”

Medizone continues to execute on plans to increase manufacturing, technical service and support, and lead generation channels to secure initial US customers for AsepticSure®.  The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.

The company will hold a conference call on Monday, September 18, 2017 at 10:00 AM EST to discuss the transition and the commercial strategy moving forward.  Call in details and presentation materials will be made available on the company’s website prior to the call (www.medizoneint.com).  Please submit questions to be addressed on the call to John Pentony, Investor Relations ([email protected]).

 

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure® system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure® system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

 

For more information, visit:

www.medizoneint.com

Email: [email protected]

 

Medizone International Announces Next Steps with FDA on AsepticSure®

Medizone International Announces Next Steps with FDA on AsepticSure®

Medizone International prepares plans to submit a marketing application to FDA for use of AsepticSure as a medical device

KALAMAZOO, Mich., Aug. 25, 2017 /PRNewswire/ — Medizone International, Inc. (OTCQB: MZEI) announced that it has received a written response from the U.S. Food and Drug Administration (“FDA”) on the Company’s 513(g) submission for disinfection of exposed surfaces and equipment within medical facilities with AsepticSure®. The FDA recommended that the Company proceed to market through the de novo classification pathway given its novel technology compared to other FDA-regulated disinfection systems. Regulation through the de novo pathway requires that the medical device be low- to moderate- risk. The company intends to support its application with data demonstrating AsepticSure’s safety and efficacy profile and low risk nature. FDA invited Company representatives to schedule follow up meetings to discuss the best approach for introduction of the AsepticSure technology into the U.S. market. Successfully completing this regulatory pathway would further support the significant competitive advantage of AsepticSure in the marketplace.

“We look forward to an ongoing productive dialogue with FDA to demonstrate the potential of AsepticSure to make a positive impact in the US healthcare sector,” commented David A. Esposito, Chairman and Interim CEO of Medizone International. “As we address these next steps with FDA, we continue to support expanding our sales and marketing efforts in other segments in the US and markets across the world.”

In November 2016, Medizone received clearance from the U.S. Environmental Protection Agency (“EPA”) (Reg. No. 90607-3) to market AsepticSure ozone disinfectant formula for use for disinfection of non-porous surfaces in hospitals, clinics, hotels, sporting venues and in the food industry, long-term care facilities, and other critical infrastructures.

The Company will continue to market AsepticSure in the US under the previously announced EPA clearance in non-medical uses as it works through the FDA regulatory process.

Medizone will continue to support commercial operations in markets outside the United States, which are not affected by this decision. In addition to the EPA clearance, the AsepticSure technology has received market approval from regulators for use and distribution in Canada, New Zealand, and Chile, and is currently seeking approvals in other countries in South America, Europe and Asia.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

AsepticSure® Receives Full Approval of International Electrical Safety Standards

AsepticSure approval of international safety standards clears path for global commercialization

 

KALAMAZOO, Mich., June 21, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company has received full electrical safety approval for all models of AsepticSure.

The testing and approval was administered by QPS Evaluation Services, a nationally and internationally accredited independent third-party testing, certification and field evaluation body headquartered in Toronto, Canada. The approval means that AsepticSure has achieved full compliance with the applicable international safety standards which provide a baseline requirement that must be met in order to pursue marketing in all jurisdictions, including Canada, USA, South America, EU, Asia, and the Middle East. Although Medizone will be required to apply for a separate approval in each country, compliance with these international safety standards will greatly facilitate this process.

“We are very pleased to announce that AsepticSure technology has received full approval for electrical safety,” said Dr. Michael Shannon, President and Director of Medical Affairs of Medizone International. “With respect to future marketing endeavors in North America, third-party certification of electrical products is mandated by law; without such certification, marketing would not be permitted. Approval of our AsepticSure system is a major step forward towards full commercialization.”

The achievement of full compliance with the relevant international safety standards provides the framework for detailed manufacturing specifications that will be incorporated in the Company’s expanded manufacturing plans.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Medizone International, Inc. (OTCQB: MZEI)

350 East Michigan Avenue – Suite 500
Kalamazoo, MI 49007

Telephone: (269) 202-5020

Email: [email protected]

Media and Investor Relations:

John Pentony

Medizone International, Inc.

Telephone: (269) 202-5020

Email: [email protected]

Social Media


Twitter:


https://twitter.com/asepticsure

CONTACT:

Medizone International, Inc. (OTCQB: MZEI)
350 East Michigan Avenue - Suite 500
Kalamazoo, MI 49007

Telephone: 269-202-5020

Email: [email protected]

INVESTOR & MEDIA RELATIONS:

John Pentony
Medizone International, Inc.

Telephone: (269) 202-5020

Email: [email protected]

SOCIAL MEDIA:

Medizone International on Twitter:

https://twitter.com/asepticsure